Phase I/II, (first-in-human), multicenter, randomized, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of HBV vaccines based on GSK viral vectors Biologicals administered in a primary vaccination – booster schedule, with sequential or joint administration of an adjuvanted therapeutic protein vaccine (GSK3528869A) in patients with chronic hepatitis B (18-65 years), on treatment with nucleotide analogues (NA). (TH HBV VV-001)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: GLAXOSMITHKLINE, SA
- Phase: I
- Execution start: 28/04/2022
- End of execution: 30/12/2023
- IP: JOSE HERNANDEZ QUERO